3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
10
Phase 1/2
3
Phase 1
3
Phase NA
1
Phase 3
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Carcinoma, Non-Small-Cell Lung
84
Breast Neoplasms
61
Prostatic Neoplasms
43
Lung Neoplasms
35
Multiple Myeloma
34
Neoplasms
27
Leukemia, Lymphocytic, Chronic, B-Cell
22
Colorectal Neoplasms
22
Parkinson Disease 4, Autosomal Dominant Lewy Body
21
Neoplasm Metastasis
19
Ovarian Neoplasms
18
Carcinoma, Renal Cell
17
Urinary Bladder Neoplasms
13
Small Cell Lung Carcinoma
13
Pancreatic Neoplasms
13
Leukemia, Myeloid, Acute
12
Endometrial Neoplasms
12
Squamous Cell Carcinoma of Head and Neck
11
Recurrence
11
Nasopharyngeal Carcinoma
11
Myasthenia Gravis
11
Triple Negative Breast Neoplasms
10
Stomach Neoplasms
10
Non-Muscle Invasive Bladder Neoplasms
10
Lymphoma, Non-Hodgkin
9
Lymphoma, Follicular
9
Fallopian Tube Neoplasms
9
Melanoma
8
Colonic Neoplasms
8
Lymphoma, Large B-Cell, Diffuse
7
Interventions
ibrutinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Waldenstrom Macroglobulinemia
×
30 days
×
Clear all
NCT01804686
2026-05-08
CAN3001
Janssen Research & Development, LLC
Phase 3
Recruiting
700 enrolled